- Research Article
- 10.1016/j.thromres.2025.109459
Genetic determinants of activated factor VII-antithrombin plasma levels and mortality in patients with coronary artery disease.
- Oct 01, 2025
- Thrombosis research
- Nicola Osti + 19 more +19
Publications from 2021 to 2026
Showing 10 of 50 papers
Genetic determinants of activated factor VII-antithrombin plasma levels and mortality in patients with coronary artery disease.
Impact of Drugs Used in Intensive Care on Routine Coagulation Testing.
Coagulation testing is commonly used in the intensive care unit (ICU) to monitor and manage the hemostatic balance, assess bleeding risk, and guide anticoagulant therapy. Routine tests used for this purpose include prothrombin time, activated partial thromboplastin time, fibrinogen, and anti-Xa assays. Some of the drugs commonly used in critically ill patients may influence coagulation assays by interacting in vitro with reagents or in vivo with coagulation pathways, thus altering the coagulation cascade and the fibrinolytic pathway. While the pharmacological effects of drugs on coagulation are usually documented, to our knowledge, no comprehensive review article has been published to date. In this review, we have conducted a critical analysis of the literature to define: (1) the impact of hydroxocobalamin, intravenous lipid emulsion, and propofol on chromogenic assays; (2) the impact of PEGylated compounds, emicizumab, recombinant activated factor VII, antibiotics, and sugammadex on chronometric assays; (3) the challenges associated with bridging anticoagulation in the ICU as well as the effect of N-acetylcystein, serotonin reuptake inhibitors, and tramadol on the hemostasis system. For each drug, we specify the routine coagulation assay that is impacted, whether this is linked to an in vitro interference or an in vivo effect, and the potential consequences on patient management.
Read moreEE799 COVID-19 Vaccination of Individuals Aged 65 Years and Over in France: Clinical and Economic Impact of Vaccine Choice
Écouter la peinture
PB0715 H3 Alters the Behavior of Endothelial Cells In Vitro
Effect of PCC on Thrombin Generation among Patients on Factor Xa Inhibitors with Major Bleeding or Needing Urgent Surgery (GAUGE): Design and Rationale
Background Direct factor Xa inhibitors (FXaIs) account for most oral anticoagulant use and FXaI-associated bleeding events are common. Clinicians have variable national and regional access to specific FXaI reversal agents such as andexanet alfa. Many centers have adopted the use of prothrombin complex concentrates (PCCs) as hemostatic therapy for FXaI-associated major bleeding events. PCC does not impact circulating FXaI levels and its mechanism of action to achieve hemostasis in FXaI-associated bleeding is uncertain. While PCC increases quantitative thrombin generation assay (TGA) parameters, it does not correct FXaI-altered thrombin generation kinetics, nor does it normalize thrombin generation. Clinical data supporting the use of PCC are based on cohort studies reporting clinical hemostatic efficacy, which is difficult to measure. The benefits of PCC for FXaI-associated bleeding beyond supportive care are uncertain.Objective GAUGE is a prospective observational study designed to measure the effects of four-factor PCC administration (Octaplex) on TGA parameters among patients with FXaI-associated bleeding or needing urgent surgery.Methods Laboratory outcomes will include the mean paired change in TGA parameters from pre- to post-PCC administration and the proportion of participants whose post-PCC TGA values fall within a defined reference range. Clinical outcomes will include hemostatic efficacy, thromboembolic complications, and all-cause death at 30 days post-PCC.Conclusion Development of a viable and universally accessible FXaI bleed management strategy is crucial. GAUGE will provide in vivo data on the effects of PCC among patients with FXaI-associated bleeding.
Read moreCorrelations between stereotypies in ASD and neurotransmitters: a systematic review
Introduction. There is evidence that neurotransmitters and their systems may be involved in the pathophysiology of motor stereotypies in Autism Spectrum Disorder. Objective. Conduct a review to assess evidence on correlations between stereotyped behaviors and changes in neurotransmitter systems, by analyzing original articles in an animal model. Method. Studies published between January 2000 and January 2021 were searched in six databases and 19 reports were selected. Reports' population, method, main results, and conclusions were extracted. Results. The analysis revealed that serotonergic, dopaminergic, glutamatergic, cholinergic, and GABAergic systems were involved in the modulation of stereotypies in animal models of ASD. In general, the administration of antagonists of serotoninergic, glutamatergic, and dopaminergic receptors causes a reduction in stereotyped behavior, and the stimulation of GABAergic and cholinergic systems, through the administration of receptor agonists, was also responsible for reducing these behaviors. There were some discrepancies in the responses depending on the routes of drug administration and the brain areas, suggesting that these factors also influence the pathophysiology of stereotypies in ASD. Conclusion. The reports suggest that the over-activation of serotoninergic, glutamatergic, and dopaminergic systems, as the suppression of GABAergic and cholinergic systems may have a direct influence on the appearance and modulation of stereotypies. Registration: PROSPERO CRD42021235397.
Read morePARP Inhibitor Inhibits the Vasculogenic Mimicry through a NF-κB-PTX3 Axis Signaling in Breast Cancer Cells
Poly (ADP-ribose) polymerase inhibitors (PARPi) are targeted therapies that inhibit PARP proteins which are involved in a variety of cell functions. PARPi may act as modulators of angiogenesis; however, the relationship between PARPi and the vasculogenic mimicry (VM) in breast cancer remains unclear. To determine whether PARPi regulate the vascular channel formation, we assessed whether the treatment with olaparib, talazoparib and veliparib inhibits the vascular channel formation by breast cancer cell lines. Here, we found that PARPi act as potent inhibitors of the VM formation in triple negative breast cancer cells, independently of the BRCA status. Mechanistically, we find that PARPi trigger and inhibit the NF-κB signaling, leading to the inhibition of the VM. We further show that PARPi decrease the expression of the angiogenic factor PTX3. Moreover, PTX3 rescued the PARPi-inhibited VM inhibition. In conclusion, our results indicate that PARPi, by targeting the VM, may provide a new therapeutic approach for triple negative breast cancer.
Read moreDP-Filter, a Rapid and Ergonomic Device to Remove Direct Thrombin Inhibitor Argatroban from Plasma for Routine Hemostasis Tests
Perioperative Coagulation Profile in Major Liver Resection for Cancer: A Prospective Observational Study
Hepatectomy-induced coagulation disturbances have been well studied over the past decade. Cumulative evidence supports the superiority of global coagulation analysis compared with conventional coagulation tests (i.e., prothrombin time or activated partial thromboplastin time) for clinical decision making. Cancer, however, represents an acquired prothrombotic state and liver resection for cancer deserves a more thorough investigation. This prospective observational study was conducted to assess the perioperative coagulation status of patients undergoing major hepatectomies for primary or metastatic hepatic malignancy. Patients were followed up to the 10th post-operative day by serial measurements of conventional coagulation tests, plasma levels of coagulation factors, and thrombin generation assay parameters. An abnormal coagulation profile was detected at presentation and included elevated FVIII levels, decreased levels of antithrombin, and lag time prolongation in thrombin generation. Serial hematological data demonstrated increased Von Willebrand factor, FVIII, D-dimer, fibrinogen and decreased levels of natural anticoagulant proteins in the early post-operative period predisposing to a hyper-coagulable state. The ratio of the anticoagulant protein C to the procoagulant FVIII was low at baseline and further declined post-operatively, indicating a prothrombotic state. Though no bleeding complications were reported, one patient experienced pulmonary embolism while under thromboprophylaxis. Overall, patients with hepatic carcinoma presenting for elective major hepatectomy may have baseline malignancy-associated coagulation disturbances, aggravating the hyper-coagulable state documented in the early post-operative period.
Read more